PurpleLab® is driven by a singular goal – to provide healthcare organizations with robust and accessible real-world data (RWD) and real-world evidence (RWE) to solve conventional and emerging challenges, including tackling medication adherence. According to the FDA[1], real-world evidence (RWE) is defined as “the clinical evidence that looks at the usage and potential benefits or…

This blog is part four in a series exploring the use of real-world evidence to produce meaningful insights in clinical pharma.  Medical affairs is a department within pharmaceutical companies that focuses on communicating scientific and clinical information to healthcare providers. Pharmaceutical medical affairs teams are responsible for activities that bridge the gap between the development…

Glucagon-like peptide-1 (GLP-1) agonists are a class of medications frequently used to treat type 2 diabetes mellitus (T2DM) and obesity.[1] This class of medications assists in lowering blood sugar levels and promotes weight loss. In addition to treating diabetics, these medications are also used to treat obesity in diabetics as well as non-diabetics.   GLP-1 drugs…

This blog is part three in a series exploring the use of real-world evidence to produce meaningful insights in clinical pharma.  Health Economics and Outcomes Research (HEOR) is a field that determines the cost-effectiveness of drugs, medical devices and other healthcare interventions. It analyzes data from various sources to build evidence around the value of…

Open claims and closed claims data serve as vital tools for comprehending patients’ progress and engagements throughout their healthcare voyage. However, which data type proves most advantageous and under what circumstances? Whether the need is to assess the cost-effectiveness of a recently introduced medication or streamline clinical trial recruitment, both open claims data and closed…

As treatment options for patients are constantly evolving, staying ahead of the curve is critical for life science companies and physicians. But with so many options in the market, how can companies gain a competitive advantage with prescribers? By leveraging real-time data that offers unprecedented insights into physician behavior and patient outcomes. PurpleLab®, a healthcare…

This blog is the fourth and final part in a series exploring how to leverage real world data to transform brand planning, launch and management created in collaboration with Fierce Pharma.  Of course, the right partner can help life sciences companies keenly focus on doing what they do best. PurpleLab® is a health-tech company driven by…

This blog is part three in a series exploring how to leverage real world data to transform brand planning, launch and management created in collaboration with Fierce Pharma.  Commercial teams at life sciences companies need to reinvent their go-to-market strategies. In doing so, however, they are apt to face a variety of challenges such as:…

This blog is part two in a series exploring how to leverage real world data to transform brand planning, launch and management created in collaboration with Fierce Pharma.  Life sciences companies are operating in a new world, one where new treatments are being developed at breakneck speed, which holds unprecedented promise for patients. However, this…